Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
April 08 2020 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to participate in a virtual fireside chat at the 19th Annual
Needham Virtual Healthcare Conference on Wednesday, April 15, at
10:40 AM EST.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators and next-in-class
muscle inhibitors as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen
Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac
muscle activator. Omecamtiv mecarbil is the subject of an
international clinical trials program in patients with heart
failure including GALACTIC-HF and METEORIC-HF. Amgen holds an
exclusive worldwide license to develop and
commercialize omecamtiv mecarbil with a sublicense held
by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a
fast skeletal muscle troponin activator (FSTA). Astellas currently
holds an exclusive worldwide license to develop and
commercialize reldesemtiv. Licenses held by Amgen and Astellas
are subject to specified co-development and co-commercialization
rights of Cytokinetics. Cytokinetics is also
developing CK-274, a novel cardiac myosin inhibitor that company
scientists discovered independent of its collaborations, for the
potential treatment of hypertrophic cardiomyopathies
(HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2
trial of CK-274 in patients with obstructive
HCM. Cytokinetics continues its over 20-year history of
pioneering innovation in muscle biology and related pharmacology
focused to diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
CytokineticsJoanna SiegallManager, Corporate
Communications, Investor Relations(425) 314-1721
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024